Mat Legut, PhD, was recently interviewed for a New York Business Journal article on Hudson Square’s emergence as a life-sciences hub.
Mat was previously a Hope Funds for Cancer Research Fellow in the lab of Dr. Neville Sanjana at the New York Genome Center (NYGC) and NYU, where he developed high-throughput approaches to discover novel regulators of the immune response.
Dr. Legut is now the CEO and CSO of OverT Bio, an NYGC spinout company. OverT Bio is a venture-backed TechBio company building next-generation cell therapies to identify and develop novel genetic modifications that will enable immune cells to overcome barriers created by tumors, leading to effective and durable immunotherapies for hard-to-treat cancers.
